The neurotensin receptor-1 promotes tumor development in a sporadic but not an inflammation-associated mouse model of colon cancer

International Journal of Cancer

Volumn 130, Issue 8, 2012, Pages 1798-1805

  Bugni, James M ^a   Rabadi, Leina Al ^a   Jubbal, Kevin ^a   Karagiannides, Iordanis ^a   Lawson, Gregory ^a   Pothoulakis, Charalabos ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aberrant crypt foci; azoxymethane; colon cancer; dextran sulfate sodium; neurotensin receptor 1

Indexed keywords

AZOXYMETHANE; CXCL2 CHEMOKINE; DEXTRAN SULFATE; INTERLEUKIN 6; MYELOPEROXIDASE; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG;

ABERRANT CRYPT FOCUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SUSCEPTIBILITY; COLITIS; COLON ADENOMA; COLON CANCER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE; GENE EXPRESSION; HISTOPATHOLOGY; MALE; MALIGNANT TRANSFORMATION; MORTALITY; MOUSE; NONHUMAN; NTSR1 GENE; PRIORITY JOURNAL; TUMOR VOLUME;

ANIMALS; AZOXYMETHANE; CHEMOKINE CXCL2; COLITIS; COLON; COLONIC NEOPLASMS; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PYRAZOLES; QUINOLINES; RECEPTORS, NEUROTENSIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84857503906     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26208     Document Type: Article

References (41)

1. Carraway R, Leeman SE,. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J Biol Chem 1973; 248: 6854-61.
2. Dumoulin V, Moro F, Barcelo A, Dakka T, Cuber JC,. Peptide YY, glucagon-like peptide-1, and neurotensin responses to luminal factors in the isolated vascularly perfused rat ileum. Endocrinology 1998; 139: 3780-6.
3. Dakka T, Dumoulin V, Chayvialle JA, Cuber JC,. Luminal bile salts and neurotensin release in the isolated vascularly perfused rat jejuno-ileum. Endocrinology 1994; 134: 603-7.
4. Castagliuolo I, Wang CC, Valenick L, Pasha A, Nikulasson S, Carraway RE, Pothoulakis C,. Neurotensin is a proinflammatory neuropeptide in colonic inflammation. J Clin Invest 1999; 103: 843-9.
5. Brun P, Mastrotto C, Beggiao E, Stefani A, Barzon L, Sturniolo GC, Palu G, Castagliuolo I,. Neuropeptide neurotensin stimulates intestinal wound healing following chronic intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 2005; 288: G621-G629.
6. Zhao D, Zhan Y, Koon HW, Zeng H, Keates S, Moyer MP, Pothoulakis C,. Metalloproteinase-dependent transforming growth factor-alpha release mediates neurotensin-stimulated MAP kinase activation in human colonic epithelial cells. J Biol Chem 2004; 279: 43547-54.
7. Ehlers RA, Zhang Y, Hellmich MR, Evers BM,. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem Biophys Res Commun 2000; 269: 704-8.
8. Ehlers RA, II, Bonnor RM, Wang X, Hellmich MR, Evers BM,. Signal transduction mechanisms in neurotensin-mediated cellular regulation. Surgery 1998; 124: 239-46; discussion 46-7.
9. Zhao D, Keates AC, Kuhnt-Moore S, Moyer MP, Kelly CP, Pothoulakis C,. Signal transduction pathways mediating neurotensin-stimulated interleukin-8 expression in human colonocytes. J Biol Chem 2001; 276: 44464-71.
10. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M,. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
11. Rozengurt E, Guha S, Sinnett-Smith J,. Gastrointestinal peptide signalling in health and disease. Eur J Surg Suppl 2002; 587: 23-38.
12. Bossard C, Souaze F, Jarry A, Bezieau S, Mosnier JF, Forgez P, Laboisse CL,. Over-expression of neurotensin high-affinity receptor 1 (NTS1) in relation with its ligand neurotensin (NT) and nuclear beta-catenin in inflammatory bowel disease-related oncogenesis. Peptides 2007; 28: 2030-5.
13. Souaze F, Viardot-Foucault V, Roullet N, Toy-Miou-Leong M, Gompel A, Bruyneel E, Comperat E, Faux MC, Mareel M, Rostene W, Flejou JF, Gespach C, et al. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis 2006; 27: 708-16.
14. Evers BM, Ishizuka J, Chung DH, Townsend CM, Jr, Thompson JC,. Neurotensin expression and release in human colon cancers. Ann Surg 1992; 216: 423-30; discussion 30-1.
15. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D, Laburthe M,. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int J Cancer 1999; 80: 448-54.
16. Tasuta M, Iishi H, Baba M, Taniguchi H,. Enhancement by neurotensin of experimental carcinogenesis induced in rat colon by azoxymethane. Br J Cancer 1990; 62: 368-71.
17. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AB, Moroski-Erkul CA, McFaline JL, Schauer DB, Dedon PC, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118: 2516-25.
18. Kokkotou E, Torres D, Moss AC, O'Brien M, Grigoriadis DE, Karalis K, Pothoulakis C,. Corticotropin-releasing hormone receptor 2-deficient mice have reduced intestinal inflammatory responses. J Immunol 2006; 177: 3355-61.
19. Nambiar PR, Girnun G, Lillo NA, Guda K, Whiteley HE, Rosenberg DW,. Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int J Oncol 2003; 22: 145-50.
20. Bissahoyo A, Pearsall RS, Hanlon K, Amann V, Hicks D, Godfrey VL, Threadgill DW,. Azoxymethane is a genetic background-dependent colorectal tumor initiator and promoter in mice: effects of dose, route, and diet. Toxicol Sci 2005; 88: 340-5.
21. Gupta AK, Pretlow TP, Schoen RE,. Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol 2007; 5: 526-33.
22. Papanikolaou A, Wang QS, Papanikolaou D, Whiteley HE, Rosenberg DW,. Sequential and morphological analyses of aberrant crypt foci formation in mice of differing susceptibility to azoxymethane-induced colon carcinogenesis. Carcinogenesis 2000; 21: 1567-72.
23. Sohn OS, Fiala ES, Requeijo SP, Weisburger JH, Gonzalez FJ,. Differential effects of CYP2E1 status on the metabolic activation of the colon carcinogens azoxymethane and methylazoxymethanol. Cancer Res 2001; 61: 8435-40.
24. Carroll RE, Goodlad RA, Poole AJ, Tyner AL, Robey RB, Swanson SM, Unterman TG,. Reduced susceptibility to azoxymethane-induced aberrant crypt foci formation and colon cancer in growth hormone deficient rats. Growth Horm IGF Res 2009; 19: 447-56.
25. Chen J, Huang XF,. The signal pathways in azoxymethane-induced colon cancer and preventive implications. Cancer Biol Ther 2009; 8: 1313-17.
26. Cohen G, Mustafi R, Chumsangsri A, Little N, Nathanson J, Cerda S, Jagadeeswaran S, Dougherty U, Joseph L, Hart J, Yerian L, Tretiakova M, et al. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res 2006; 66: 5656-64.
27. Sinicrope FA, Gill S,. Role of cyclooxygenase-2 in colorectal cancer. Cancer Metastasis Rev 2004; 23: 63-75.
28. Mishra L, Shetty K, Tang Y, Stuart A, Byers SW,. The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene 2005; 24: 5775-89.
29. Taketo MM,. Wnt signaling and gastrointestinal tumorigenesis in mouse models. Oncogene 2006; 25: 7522-30.
30. Grivennikov SI, Karin M,. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev 2010; 21: 11-19.
31. Dougherty U, Sehdev A, Cerda S, Mustafi R, Little N, Yuan W, Jagadeeswaran S, Chumsangsri A, Delgado J, Tretiakova M, Joseph L, Hart J, et al. Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model. Clin Cancer Res 2008; 14: 2253-62.
32. Biswas S, Chytil A, Washington K, Romero-Gallo J, Gorska AE, Wirth PS, Gautam S, Moses HL, Grady WM,. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer. Cancer Res 2004; 64: 4687-92.
33. Ishikawa TO, Herschman HR,. Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1 or COX-2 expression. Carcinogenesis 2010; 31: 729-36.
34. Roberts RB, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW,. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc Natl Acad Sci USA 2002; 99: 1521-6.
35. Zhao D, Zhan Y, Zeng H, Koon HW, Moyer MP, Pothoulakis C,. Neurotensin stimulates expression of early growth response gene-1 and EGF receptor through MAP kinase activation in human colonic epithelial cells. Int J Cancer 2007; 120: 1652-6.
36. Lemaire I,. Neurotensin enhances IL-1 production by activated alveolar macrophages. J Immunol 1988; 140: 2983-8.
37. Waugh DJ, Wilson C,. The interleukin-8 pathway in cancer. Clin Cancer Res 2008; 14: 6735-41.
38. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-7.
39. Chao C, Tallman ML, Ives KL, Townsend CM, Jr, Hellmich MR,. Gastrointestinal hormone receptors in primary human colorectal carcinomas. J Surg Res 2005; 129: 313-21.
40. Wang X, Jackson LN, Johnson SM, Wang Q, Evers BM,. Suppression of neurotensin receptor type 1 expression and function by histone deacetylase inhibitors in human colorectal cancers. Mol Cancer Ther 2010; 9: 2389-98.
41. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AB, Moroski-Erkul CA, McFaline JL, Schauer DB, Dedon PC, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008; 118: 2516-25.